CDMO Blog

Scaling-Up Production of Pluripotent Stem Cells Part 2 – Key Considerations for Successful Scale-Up

close

Categories

See More

Subscribe to Email Updates

Popular Stories

Viral Aggregation in Downstream Processing of Lentiviral Vectors May 11, 2020
IQ, OQ and PQ: Why Are They Important in the Manufacturing of Cell and Gene Therapies? Oct 24, 2019
5 Considerations for Scaling-Up PSC-Derived Cell Therapies Mar 04, 2021
Five Steps to Ensure Your Cell and Gene Therapy Product Is GMP Compliant Oct 30, 2019
Planning Is Everything - Quality Control Testing in Cell and Gene Therapy Oct 30, 2019
Categories | Subscribe | Popular
09 Jun 2021

Scaling-Up Production of Pluripotent Stem Cells Part 2 – Key Considerations for Successful Scale-Up

In Part 1 of this series we covered some basic definitions and reviewe...

04 Mar 2021

5 Considerations for Scaling-Up PSC-Derived Cell Therapies

A core regenerative medicine approach is cell replacement for the repa...

24 Oct 2019

How Can a Closed CAR-T Manufacturing Process De-Risk Your Process, Reduce Costs and Improve Efficiency?

In a previous post we introduced chimeric antigen receptor T-cell (CAR...

24 Oct 2019

What is a Bioreactor and How is it Used in Cell and Gene Therapy?

Simply put, a bioreactor is a stand-alone cell culture vessel enabled ...

22 Oct 2019

How Can a Contract Development and Manufacturing Organization (CDMO) Advance a Cell & Gene Therapy Product?

  Making the Decision to Engage a CDMO

Tell us what you thought about this post.
Business people meeting around table in modern space

Subscribe to our blog.

Receive updates on the latest trends in cell & gene therapy.

Subscribe to Email Updates

© 2021 All Rights Reserved